ArticleCommunications biology2025
Engineering a heparin-mimetic biomaterial to promote tissue vascularization.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Matrix degradation promotes fibronectin deposition and spatial remodeling in 3D.Cell reports. Physical science · 2026Article
- Assessing the Angiogenic Potential of Poly(ε-Caprolactone) PCL/Bioactive Glass Composites in a Co-Culture Model of ASCs and HMEC-1.Biomedicines · 2026Article
- Editorial: Advances in polymer-based biomaterials for tissue engineering and regenerative medicine.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A major challenge in tissue engineering involves the development of synthetic biomaterials that effectively induce and maintain functional vascularization of engineered tissue constructs post implantation. While conjugating heparin to a dextran hydrogel developed a pro-angiogenic scaffold that led to substantial endothelial multicellular assembly in vitro and enhanced host vessel invasion in vivo, the inherent anti-coagulant bioactivities of native heparin elicited substantial local bleeding upon implantation. To decouple the pro-angiogenic effects from the anti-coagulant activity, we developed a synthetic, heparin-mimetic material by introducing sulfate adducts to the dextran backbone. These heparin-mimetic hydrogels bound and immobilized growth factors, enhanced angiogenic signaling, and promoted both in vitro vascular network formation in 3D and in vivo tissue microvascularization to a similar extent as heparin conjugated hydrogels, but without inducing local bleeding at implantation sites. This development of a fully synthetic, highly tunable angiogenic biomaterial provides a new material system to engineer functional vascularized tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.